AR101814A1 - Partícula de tipo virus flavivirus - Google Patents

Partícula de tipo virus flavivirus

Info

Publication number
AR101814A1
AR101814A1 ARP150102897A ARP150102897A AR101814A1 AR 101814 A1 AR101814 A1 AR 101814A1 AR P150102897 A ARP150102897 A AR P150102897A AR P150102897 A ARP150102897 A AR P150102897A AR 101814 A1 AR101814 A1 AR 101814A1
Authority
AR
Argentina
Prior art keywords
flavivirus
type particle
virus flavivirus
flavivirus type
virus
Prior art date
Application number
ARP150102897A
Other languages
English (en)
Inventor
Ueno Ryuji
Akahata Wataru
Original Assignee
Vlp Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Llc filed Critical Vlp Therapeutics Llc
Publication of AR101814A1 publication Critical patent/AR101814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona una partícula de tipo viral que comprende una o varias proteínas estructurales de flavivirus, y una composición o vacuna que la comprende, su uso en la prevención o el tratamiento de infección por flavivirus. La proteína estructural de flavivirus contiene al menos una alteración de aminoácidos en la región de envoltura. Los ejemplos de flavivirus contienen virus del dengue.
ARP150102897A 2014-09-11 2015-09-11 Partícula de tipo virus flavivirus AR101814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462048897P 2014-09-11 2014-09-11

Publications (1)

Publication Number Publication Date
AR101814A1 true AR101814A1 (es) 2017-01-11

Family

ID=55453731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102897A AR101814A1 (es) 2014-09-11 2015-09-11 Partícula de tipo virus flavivirus

Country Status (13)

Country Link
US (1) US10098943B2 (es)
EP (1) EP3191589A4 (es)
JP (1) JP6942309B2 (es)
KR (1) KR102532832B1 (es)
CN (1) CN106687590B (es)
AR (1) AR101814A1 (es)
AU (1) AU2015313650B2 (es)
CA (1) CA2960102C (es)
MX (1) MX2017003117A (es)
PH (1) PH12017500450A1 (es)
SG (1) SG11201701669PA (es)
TW (1) TWI695842B (es)
WO (1) WO2016038895A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016210127A1 (en) * 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
KR20200051693A (ko) * 2017-09-11 2020-05-13 텐겐 바이오메디컬 컴퍼니 포유동물-특이적 성장-결함 아르보바이러스
CN113651885B (zh) * 2018-04-04 2022-04-15 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
KR101970963B1 (ko) * 2018-12-19 2019-04-23 주식회사 엠디헬스케어 황열 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
SG11202100677VA (en) * 2019-05-28 2021-02-25 Chiang Mai Univ Mature virus-like particles of flaviviruses

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
ES2129461T3 (es) 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP0854929A1 (en) 1995-09-27 1998-07-29 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
JP2002507393A (ja) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 抗原ライブラリー免疫
AU2674299A (en) * 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
WO2002096939A2 (en) 2001-05-30 2002-12-05 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
SG165155A1 (en) 2002-02-26 2010-10-28 Maxygen Inc Novel flavivirus antigens
WO2003102133A2 (en) * 2002-05-13 2003-12-11 The Regents Of The University Of California Chemical modifications to polymer surfaces and the application of polymer grafting to biomaterials
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
AU2003295470A1 (en) 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
MXPA05012754A (es) 2003-05-29 2006-05-17 Army Medical Res Inst For I Vacunas virales atenuadas vivas para virus de encefalitis equina oriental.
JP4506301B2 (ja) 2003-09-30 2010-07-21 ブラザー工業株式会社 インクカートリッジ及びインクジェットプリンタ
WO2005067478A2 (en) 2003-12-01 2005-07-28 Dow Global Technologies Inc. Recombinant icosahedral virus like particle production in pseudomonads
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
AU2007200847B2 (en) * 2004-07-27 2010-06-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
PT1802336E (pt) 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Vacinas de dose inicial/reforço para a malária
JP4819792B2 (ja) 2005-02-16 2011-11-24 国立大学法人東京工業大学 改変されたウイルスカプシドタンパク質及びその使用
WO2006133396A2 (en) 2005-06-08 2006-12-14 Dana-Farber Cancer Institute Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2007100098A1 (ja) 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
US20100120092A1 (en) 2006-08-30 2010-05-13 Hepgenics Pty Ltd. Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
AU2008338803B2 (en) 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
AU2009320287B2 (en) 2008-11-26 2015-10-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
EP2477650B8 (en) 2009-09-18 2019-10-09 FRAUNHOFER USA Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
CN101948850A (zh) * 2010-08-13 2011-01-19 中国疾病预防控制中心病毒病预防控制所 登革病毒病毒样颗粒的制备方法及应用
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
US9284356B2 (en) * 2011-07-12 2016-03-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of a west nile virus CD4 T cell epitope and use thereof
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
US20150265694A1 (en) 2011-10-25 2015-09-24 Florida Gulf Coast University Board Of Trustees Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
SG10201606635SA (en) 2012-02-16 2016-10-28 Vlp Therapeutics Llc Virus like particle composition
BR112014024612A2 (pt) * 2012-04-02 2021-06-08 Univ North Carolina Chapel Hill ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
US9895435B2 (en) 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
WO2014196648A1 (en) 2013-06-03 2014-12-11 Vlp Therapeutics, Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
WO2015139784A1 (en) 2014-03-18 2015-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
EP3309251A4 (en) 2015-06-12 2019-03-13 Mie University VIRAL VECTOR OF PARAINFLUENZA TYPE 2 HUMAN AND VACCINE
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
EA035921B1 (ru) 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Also Published As

Publication number Publication date
EP3191589A1 (en) 2017-07-19
EP3191589A4 (en) 2018-05-09
CA2960102C (en) 2023-10-24
WO2016038895A1 (en) 2016-03-17
BR112017004770A2 (pt) 2017-12-12
KR102532832B1 (ko) 2023-05-16
US10098943B2 (en) 2018-10-16
PH12017500450A1 (en) 2017-07-31
SG11201701669PA (en) 2017-04-27
JP6942309B2 (ja) 2021-09-29
JP2017528139A (ja) 2017-09-28
TWI695842B (zh) 2020-06-11
KR20170055513A (ko) 2017-05-19
US20160074501A1 (en) 2016-03-17
AU2015313650B2 (en) 2021-07-08
BR112017004770A8 (pt) 2023-04-11
CA2960102A1 (en) 2016-03-17
CN106687590A (zh) 2017-05-17
CN106687590B (zh) 2021-08-03
TW201612190A (en) 2016-04-01
MX2017003117A (es) 2017-06-14
AU2015313650A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
CL2016000300A1 (es) Métodos terapéuticos
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.